Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: J Biomed Mater Res A. 2018 Feb 23;106(6):1753–1764. doi: 10.1002/jbm.a.36360

Figure 6.

Figure 6

In vivo tumor targeting of PLGA-PEG-AXT050 NPs to human triple-negative breast cancer tumors. A-B PLGA-PEG-AXT050 NPs accumulate in human TNBC tumors and exhibit a biphasic relationship between the level of AXT050 conjugation and TNBC tumor accumulation with 10% PLGA-PEG-AXT050/90% PLGA-mPEG NPs being optimal. C The half-life of the 100% PLGA-PEG-AXT050 NPs was 45 minutes and longer half-lives were observed with 10% NPs (103 min) and 0% NPs (110 min), which were composed of increasing levels of PLGA-mPEG rather than PLGA-PEG-AXT050. D Animal imaging demonstrates the whole body biodistribution of the peptide nanoparticles, with the greatest tumor accumulation being with the 10% NPs.